This inventor holds 4 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Cancer Research Technology Limited, The Institute of Cancer Research: Royal Cancer Hospital, The Institute of Cancer Research. Active years: 2021-2025.
Company Filing History:
4 out of 268 
3 out of 54 
1 out of 24 
Years Active: 2021-2025
Title: Matthew Garth Lloyd: Innovator in Cancer Research
Introduction
Matthew Garth Lloyd is a notable inventor based in London, GB. He has made significant contributions to the field of cancer research, particularly through his innovative work on BCL6 inhibitors. With a total of 4 patents to his name, Lloyd's inventions are aimed at addressing critical health challenges.
Latest Patents
Lloyd's latest patents include the development of benzimidazolone derived inhibitors of BCL6. These compounds function as inhibitors of B-cell lymphoma 6 activity, which is crucial in the treatment of proliferative disorders such as cancer. The invention also encompasses processes for the preparation of these compounds, pharmaceutical compositions that include them, and their application in treating diseases where BCL6 activity is implicated. Another patent focuses on BCL6 inhibitors, detailing similar compounds and their therapeutic uses.
Career Highlights
Throughout his career, Matthew Garth Lloyd has worked with esteemed organizations such as Cancer Research Technology Limited and the Institute of Cancer Research: Royal Cancer Hospital. His work in these institutions has allowed him to contribute to groundbreaking research and development in cancer therapies.
Collaborations
Lloyd has collaborated with notable colleagues, including Benjamin Richard Bellenie and Kwai Ming Jack Cheung. These partnerships have further enhanced his research efforts and innovation in the field.
Conclusion
Matthew Garth Lloyd stands out as a dedicated inventor whose work in cancer research has the potential to make a significant impact on treatment options. His innovative patents reflect his commitment to advancing medical science and improving patient outcomes.